



COMPANY OVERVIEW

OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies for the treatment of cancer. The Company's investigational technology, ImmunoPulse®, is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, OncoSec's lead program, ImmunoPulse® IL-12, demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. ImmunoPulse® IL-12 is currently in Phase II development for several indications, including metastatic melanoma and triple negative breast cancer. In addition to ImmunoPulse® IL-12, the Company is also seeking to identify and develop new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit www.oncosec.com.

RECENT NEWS

OncoSec Medical Incorporated Announces Closing of \$23.0 Million Public Offering of Common Stock

Feb 6 2018, 8:30 AM EST

OncoSec Medical Incorporated Prices \$20.0 Million Public Offering of Common Stock

Feb 1 2018, 9:21 AM EST

STOCK OVERVIEW

Symbol	ONCS	Exchange	NASDAQ
Shares OS	35,517,727	Market Cap	\$62.87M
Last Price	\$1.77	52-Week Range	\$0.88 - \$2.95
Fiscal Year End	December 31		

MANAGEMENT TEAM

Daniel J. O'Connor

Chief Executive Officer and Director

Punit Dhillon

Co-founder, Director, and President

Richard B. Slansky

Chief Financial Officer

Christopher G. Twitty, Ph.D.

Chief Scientific Officer

Dr. Robert H. Pierce, MD

Chief Scientific Strategist

Sharron Gargosky, PhD

Chief Clinical and Regulatory Officer

Sheela Mohan-Peterson

Chief Legal and Compliance Officer

ONCOSEC MEDICAL INCORPORATED

5820 Nancy Ridge Drive
San Diego, CA 92121
US

INVESTOR RELATIONS

T: 855-ONCOSEC (855-662-6732)
investors@oncosec.com

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.